Association of post-operative ctDNA detection with outcomes of patients with early breast cancers
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Circulating tumor DNA (ctDNA) analysis in early breast cancer patients after surgery can detect residual disease. Absence of ctDNA post-surgery is linked to better distant recurrence-free survival, suggesting potential for treatment de-escalation.
Area Of Science
- Oncology
- Molecular Diagnostics
- Genomics
Background
- Early breast cancer (EBC) management requires accurate prognostication.
- Assessing molecular residual disease (MRD) post-surgery is crucial for treatment decisions.
- Circulating tumor DNA (ctDNA) is a promising biomarker for MRD detection.
Purpose Of The Study
- To evaluate ctDNA detection after primary surgery in EBC patients.
- To determine if post-surgical ctDNA identifies MRD and predicts relapse.
- To associate ctDNA status with relapse-free survival (RFS) and distant recurrence-free survival (DRFS).
Main Methods
- Retrospective analysis of plasma samples from 48 EBC patients.
- Samples collected pre-surgery, post-surgery, and pre-adjuvant therapy.
- Personalized, tumor-informed ctDNA analysis using next-generation sequencing (Signatera™).
Main Results
- ctDNA was detected in 64.5% of patients pre-surgery and 35.4% post-surgery.
- Post-surgical ctDNA detection was associated with worse DRFS (HR=5.5, P=0.04).
- ctDNA detection anticipated clinical relapse by a median of 16 months.
Conclusions
- ctDNA is detectable in treatment-naive EBC patients after surgery.
- Absence of post-surgical ctDNA correlates with improved DRFS.
- These findings support trials investigating de-escalation of systemic therapy based on ctDNA status.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
